| Date Filed | Type | Description |
| 11/22/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 11/19/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/12/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/12/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/12/2019 |
4
| Stalfort Sean (Director) has filed a Form 4 on Dova Pharmaceuticals Inc.|
Txns:
| Unknown transaction of 635,665 shares
@ $27.5, valued at
$17.5M
|
|
| 11/12/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/12/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/12/2019 |
4
| Laliberte Kevin (Sr. VP, Product Development) has filed a Form 4 on Dova Pharmaceuticals Inc.|
Txns:
| Disposed/sold 4,761 shares
@ $0
Disposed/sold 115,500 options to buy
@ $3.73, valued at
$430.8k
Disposed/sold 24,750 options to buy
@ $3.73, valued at
$92.3k
Disposed/sold 50,000 options to buy
@ $8.82, valued at
$441k
Disposed/sold 10,000 options to buy
@ $16.08, valued at
$160.8k
|
|
| 11/12/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/12/2019 |
4
| Hoitt Jason (Chief Commercial Officer) has filed a Form 4 on Dova Pharmaceuticals Inc.|
Txns:
| Disposed/sold 9,970 shares
@ $0
Disposed/sold 250,000 options to buy
@ $6.07, valued at
$1.5M
|
|
| 11/12/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/12/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/12/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/12/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 11/12/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 11/12/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 11/12/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 11/12/2019 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 11/12/2019 |
8-K
| Quarterly results |
| 11/12/2019 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 11/12/2019 |
10-Q
| Quarterly Report for the period ended September 30, 2019 |
| 11/01/2019 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 11/01/2019 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 10/29/2019 |
GN
| SHAREHOLDER ALERT: WeissLaw LLP Reminds DOVA, TRCB, EEI, and UCFC Shareholders About Its Ongoing Investigations |
| 10/11/2019 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 10/11/2019 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 10/03/2019 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 10/03/2019 |
8-K
| Quarterly results |
| 10/02/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2019 |
4
| Hoitt Jason (Chief Commercial Officer) has filed a Form 4 on Dova Pharmaceuticals Inc.|
Txns:
| Sold 2,387 shares
@ $28, valued at
$66.8k
|
|
| 10/02/2019 |
4
| Laliberte Kevin (Sr. VP, Product Development) has filed a Form 4 on Dova Pharmaceuticals Inc.|
Txns:
| Sold 3,100 shares
@ $28, valued at
$86.8k
Sold 596 shares
@ $28, valued at
$16.7k
|
|
|